Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
182.08
+3.91 (2.19%)
At close: Jun 26, 2026, 4:00 PM EDT
182.85
+0.77 (0.42%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Revolution Medicines stock have an average target of 185.11, with a low estimate of 140 and a high estimate of 263. The average target predicts an increase of 1.66% from the current stock price of 182.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock from 21 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 17 | 17 | 17 | 17 | 16 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 21 | 21 | 21 | 22 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 25, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $205 | Buy | Maintains | $205 | +12.59% | Jun 25, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $175 → $200 | Buy | Reiterates | $175 → $200 | +9.84% | Jun 25, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $185 → $212 | Buy | Reiterates | $185 → $212 | +16.43% | Jun 25, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $263 | Buy | Maintains | $263 | +44.44% | Jun 23, 2026 |
Financial Forecast
Revenue This Year
102.95M
Revenue Next Year
830.24M
from 102.95M
Increased by 706.44%
EPS This Year
-8.01
from -5.95
EPS Next Year
-5.70
from -8.01
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 295.1M | 2.4B | |
| Avg | 103.0M | 830.2M | |
| Low | n/a | 143.4M |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 2,245.4% | 361.0% |
| Avg | 706.4% | 120.1% |
| Low | 39.3% | -17.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -7.20 | 0.96 | |
| Avg | -8.01 | -5.70 | |
| Low | -8.81 | -10.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.